IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
DEVELOPMENT AND EVALUATION OF URSOLIC ACID LOADED EUDRAGIT-E NANOCARRIER FOR CANCER THERAPY

Author: NEERAJ SETHI, PRASHANT BHARDWAJ, SANDEEP KUMAR, NEERAJ DILBAGHI
Abstract: Ursolic acid (UA), a pentacyclic triterpenoid could hinder the progression of tumor cells but its potential for clinical utilization is significantly hampered by its poor solubility due to its hydrophobic nature. The present study is aimed to develop a novel polymeric platform of Ursolic acid loaded Eudragit-E nanoparticles (UENPs) using nanoprecipitation strategy. The UENPs were characterized for encapsulation potential, size, morphology, zeta potential, release rate studies, and FTIR. The drug release profile was evaluated for in vitro antioxidant and anticancer activity. We observed that UENPs possess particle size in the range of 18 - 35 nm and encapsulation efficiency of 59.98%. Furthermore, Eudragit-E at 2 mg/ml and poloxamer at 0.5% w/w were competent to produce isolated and free flowing nanoparticles. The in vitro anti-cancer assay of UENPs demonstrated inhibition of cancer cells to a greater extent and induced programmed cell death in A-549, MCF-7 & Hela cell lines as compared to drug particles alone. These findings suggest the utilization of UA entrapped Eudragit-E nanoparticles as advance drug delivery tool to combat cancer.
Keyword: Ursolic acid, Polymeric Nanoplatforms, Particle size, Anti-cancer activity
DOI: https://doi.org/10.31838/ijpr/2019.11.02.065
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477